

Artificial Intelligence in Tissue Engineering for cardiovascular treatment

A Project Report Submitted to

Galgotias University

In Partial Fulfilment of the Requirements

for the Degree of

BACHELOR OF PHARMACY

By

MD SHAYAN

Enrolment No-19021020154

Under the Supervision of

Dr. Ajay Pal Singh

Professor

Galgotias University, Greater Noida.



**GALGOTIAS
UNIVERSITY**

DAPARTMENT OF PHARMACY

GALGOTIAS UNIVERSITY

Greater Noida, Uttar Pradesh-201310

May,202

Artificial Intelligence in Tissue Engineering for cardiovascular treatment

A Project Report Submitted to

Galgotias University

In Partial Fulfilment of the Requirements

for the Degree of

BACHELOR OF PHARMACY

By

MD SHAYAN

Enrolment No-19021020154

Under the Supervision of

Dr. Ajay Pal Singh

Professor

Galgotias University, Greater Noida.



**GALGOTIAS
UNIVERSITY**

DEPARTMENT OF PHARMACY

GALGOTIAS UNIVERSITY

Greater Noida, Uttar Pradesh-201310

May,2023



CERTIFICATE

This is to certify that project work entitled “**Artificial Intelligence in Tissue Engineering for cardiovascular treatment**” done by **Md Shayan**, is a bonafide research work under the supervision and guidance of **Dr. Ajay Pal Singh**, Professor, School of Medical and Allied Sciences, Greater Noida. The work is completed and ready for evaluation in partial fulfillment for the award of Bachelor of Pharmacy during the academic year 2022-2023. The project report has not formed the basis for the award of any Degree/Diploma/Fellowship or other similar title to any candidate of any University.

Date:

Prof. (Dr.) Pramod Kumar Sharma
Dean
School of Medical and Allied Sciences
Galgotias University
Greater Noida (U.P.)

BONAFIDE CERTIFICATE

This to certify that the project work entitled “**Artificial Intelligence in Tissue Engineering for cardiovascular treatment**” is the bonafide research work done by **Md Shayan**, who carried out the research work under my supervision and guidance for the award of Bachelor of Pharmacy under Galgotias University, Greater Noida during the academic year 2022-2023. To the best of my knowledge the work reported herein is not submitted for award of any other degree or diploma of any other Institute or University.

Dr. Ajay Pal Singh

Guide

Professor

School of Medical and Allied Sciences

Galgotias University

Greater Noida (U.P.)

DECLARATION

I hereby declare that the work embodied in this project report entitled “**Artificial Intelligence in Tissue Engineering for cardiovascular treatment**” in Partial fulfillment of the requirements for the award of Bachelor of Pharmacy, is a record of original and independent research work done by me during the academic year 2022-23 under the supervision and guidance of **Dr. Ajay Pal Singh**, Professor, School of Medical and Allied Sciences, Galgotias University, Greater Noida. I have not submitted this project for award of any other degree or diploma of any other Institute or University.

Date:

(Mr. Md Shayan)

Place:

Name and Signature of candidate

Acknowledgement

It gives me immense gratification to place on records my profound gratitude and sincere appreciation to each and everyone who has helped me in this endeavour. I gratefully acknowledge **Prof. (Dr.) Pramod Kumar Sharma**, Dean, School of Medical and Allied Sciences, Galgotias University, Uttar Pradesh for his advice. Supervision and crucial contribution made a backbone of this review and so to this thesis.

I wish to express my gratefulness to my supervisor of **Dr. Ajay Pal Singh**, Professor, Galgotias University, Greater Noida for his constant guidance in dealing with the project.

I wish to express my gratitude to my colleagues and friends for their constant encouragement and sport.

Lastly, I have absolutely no words to express my feeling of gratitude to the staff members of marketing executive and sales representatives for their full co-operation and valuable suggestions in the completion of my project work.

At last, but not least, I would like to thank God for giving me patience and power for the successful completion of the project.

Md. Shayan

B. Pharma VIII Sem

Enrollment-No-19021020154

Galgotias University,

Greater Noida, Uttar Pradesh

Table of Contents

Acknowledgement	v
List of Figures.....	vii
List of abbreviations	viii
Abstract	ix
1. Introduction	10
2. Applications of artificial intelligence in cardiology.....	13
2.1 Electrocardiography	13
3. Prediction of Cardiovascular Morbidity or Mortality.....	15
3.1 Transthoracic echocardiography.....	15
4. Cardiac computed tomography angiography	16
5. Gene mutants in human cardiac failure.....	18
5.2 Potential of CRISPR/Cas systems in cardiac tissue engineering	18
6. Stem cell differentiation.....	20
7. Limitations of AI-Based Technologies	21
8. Challenges and Future Prospects	22
9. Regulation and Evidence	23
10. Conclusion.....	24
References.....	26

List of Figures

S. No.	Title	Page No.
01.	Classification of Cardiovascular Discovery pipeline	12
02.	Mechanism of Stem Cell Differentiation	20

List of abbreviations

AI - Artificial intelligence
ML - Machine Learning
CMs - Cardiomyocytes
CPR - Cardiopulmonary reanimation
VT - Ventricular tachycardia
SVM - Support vector machines
ECGs - Electrocardiograms
FRS - Framingham Threat Score
CACs - Coronary roadway calcium scoring
HDR-Homology - directed repair

Abstract

The goal of this article is to evaluate how recent developments in fabrication techniques, genome editing, and machine learning are influencing the future of cardiac tissue engineering. AI algorithms have been used to diagnose, segment and reconstruct images, quality control, prognosis, Phen grouping, and scientific discovery in cardiology. AI is being used to automate electrocardiogram interpretation and patient categorization and prognosis. ML models can detect and compute a variety of cardiac parameters, including P and T waves, QRS complexes, heart rate, cardiac axis, ECG interval lengths, ST-changes, and common rhythm abnormalities. A 34-layer DNN has recently been developed that can recognise with more recall a human cardiologist. A variety of machine learning (ML), including SVMs, gradient boosting machines (GBMs), MLNNs, it is used to estimate patients' likelihood of experiencing an ischemic stroke.

Transthoracic echocardiography provides instantaneous visualisation of the heart's structure, allowing for rapid diagnosis of structural abnormalities. An innovative method for calculating LVEF automatically from 2-D echocardiographic pictures using AI-learned pattern recognition. CRISPR/Cas9 systems used to design for cell of cardiac, with potential such as enhanced the avoidance of the body's immunological response. CRISPR/Cas9 technology can be used to improve cell homing, delete inactive genes, model cardiovascular disease, reduce immunogenicity, and protect hESC-derived allografts from immune rejection.

Keywords: Recent development, Quality control, Genome editing, Fabrication technique, Machine learning, Cardiac prognosis.

1. Introduction

Numerous mechanisms, such as necrosis, apoptosis, and oncosis (or ischemia cell death), put cardiomyocytes (CMs) at risk for heart failure. When it comes to regeneration, the adult human heart ranks near the bottom. Recent studies have shown a link between necrosis, or premature cell death due to physical or chemical stress, and apoptosis, or programmed cell death, in pathological settings of cardiac illness. In the parts of the heart injured by myocardial infarction, for instance, fibrillar collagen and/or fibroblast-like cells replace CMs [1]. Necrosis and oncosis are both form of cell death caused by damage to the cell, but oncosis is distinguished from necrosis by the fact that the cell enlarges rather than shrinks following injury. More than 38 million people worldwide suffered from heart failure that year, including over 6.5 million in the United States alone. In addition, cardiac aetiology and ageing are linked to a substantial and continuing rise in the risk of heart disease. All of these processes are at odds with one another because the cell turnover rate in mature mammalian CMs is only about 0.3% to 1.0% per year. For these and other reasons, the heart is an appealing research subject for tissue engineers. These investigations will shed light on the process of heart healing and improve cardiac function via tissue engineering, opening up exciting new avenues of research [2].

VF is the most common type of cardiac arrest and occurs when the heart's ventricles (the lower chambers) develop a rapid, chaotic, and irregular electrical activity, leading to ineffective contractions. This results in a loss of coordinated pumping action, and the heart is unable to effectively circulate blood, in ventricular fibrillation, the normal electrical signals that regulate the heart's conduction come chaotic and disorganized, causing the ventricles to quake or fibrillate rather of constricting typically [3]. As a result, the heart is unfit to pump blood effectively, and blood inflow to the body's vital organs is oppressively compromised. Ventricular fibrillation can do due to colourful underpinning causes, including heart complaint. similar as coronary roadway complaint, former heart attack, heart failure, electrolyte imbalances, medicine toxin, trauma, or other medical conditions [4]. Certain threat factors, similar as a history of heart complaint, family history of unforeseen cardiac arrest or arrhythmias, and certain life choices, similar as smoking, inordinate alcohol consumption, and lawless medicine use, may increase the threat of ventricular fibrillation. The treatment for ventricular fibrillation is immediate and implves cardiopulmonary reanimation (CPR) to give artificial rotation and, immaculately, early defibrillation with an automated external defibrillator (AED) to deli an electric shock to the heart to restore normal meter [5]. In addition to defibrillation, advanced cardiac life support (ACLS) measures, including specifics, intubation, and other interventions, may be necessary to manage ventricular fibrillation and restore normal heart function. It is important to seek exigency medical attention incontinently if you suspect someone is passing ventricular fibrillation or any other form of cardiac arrhythmia. Prompt recognition and applicable treatment are critical in managing ventricular fibrillation and perfecting issues [5,6]. VT is a type of cardiac arrest characterized by a rapid and regular electrical activity in the ventricles, but the contractions are ineffective, resulting in little or no blood flow Pulseless ventricular tachycardia (VT) is a type of cardiac arrhythmia where the ventricles (the lower chambers) of the heartbeat fleetly and rhythmically, but there is no effective compression of the heart and no palpable palpitation. Pulseless VT is a life-changing condition that can lead to cardiac arrest and requires immediate medical attention.

In pulseless VT, the electrical signals that regulate the heart's conduction come disorganized and rapid-fire, performing in a fast and irregular twinkle. Still, the ventricles are not effectively pumping blood to the body's organs due to ineffective conduction. This can beget an unforeseen loss of knowledge, and if not treated instantly, can progress to cardiac arrest where the heart stops pumping blood effectively. Pulseless VT can do due to colourful underpinning causes, including heart complaint, similar as coronary roadway complaint, former heart attack, heart failure, electrolyte imbalances, medicine toxin, trauma, or other medical conditions.

Certain threat factors, similar as a history of heart complaint, family history of unforeseen cardiac arrest or arrhythmias, and certain life choices, similar as smoking, inordinate alcohol consumption, and lawless medicine use, may increase the threat of pulseless VT. The treatment for pulseless VT is immediate and involves cardiopulmonary reanimation (CPR) to give artificial rotation and, immaculately, early defibrillation with an automated external defibrillator (AED) to deliver an electric shock to the heart to restore normal rhythm. However, advanced cardiac life support (ACLS) measures, including specifics, if pulseless VT persists despite defibrillation. It is important to seek exigency medical attention incontinently if you suspect someone is passing pulseless VT or any other form of cardiac arrhythmia. Prompt recognition and applicable treatment are critical in managing pulseless VT and perfecting Issues. One area that has advantaged from AI's recent rise, especially machine literacy and deep literacy, is cardiac towel engineering. The purpose of machine literacy (ML) is to develop algorithms that can sift through large quantities of data in hunt of recreating patterns that can latterly be used to make prognostications about the future. Two of the multitudinous areas where ML has demonstrated to be of substantial implicit use are the disciplines of natural data analysis and fiscal vaticination [7]. ML encompasses a broad variety of styles whereby a computer excerpts features, "learns" how those rates are generally linked with a given group, and also predicts about that group using the point patterns of incoming samples. Machine literacy styles exceed when working with petabyte- or terabyte- scale datasets. While the inner workings of ML algorithms' retired layers are not always clear, they can be trained to efficiently find input- affair correlations. The development of structures and algorithms that might drastically lessen or indeed exclude the need for mortal engagement in these processes is still in the evidence- of- conception phase in this sphere. ML has been used for contractility of mortal pluripotent stem cell- deduced synthetic cardiac towel histopathological image analysis and automated medicine bracket grounded on protein- ligand list affinity. A Pareto- grounded tone- learning evolutionary algorithm and an adaptive neural fuzzy conclusion system might be employed for control and optimisation in 3D altar structure [8]. Stemness traits related to oncogenic dedifferentiation 3D altar design, differences in the original medium, and driving cellular isolation pathways in CM development have all been linked using ML and evolutionary algorithms. AI- grounded approaches are a suite of programmes for learning from data and doing smart analysis [9]. Machine literacy and deep literacy are two exemplifications of AI- grounded styles. Machine literacy relies on the flawless combination of data- ferocious styles similar as naïve Bayesian, support vector machines (SVM), and deep neural network updates [10]. Asystole, also known as "flatline," occurs when the heart has no electrical activity and is not contracting. Asystole is considered a type of cardiac arrest, but it is often associated with a very poor prognosis. where there is no electrical exertion in the heart, performing in the absence of any perceptible twinkle or palpitation. Asystole is a life changing condition and represents

the most severe form of cardiac arrest, with a veritably poor prognostic if not instantly treated. In asystole, the heart's electrical exertion is absent or inadequate to induce effective condensation, performing in the complete conclusion of blood inflow to the body's vital organs [11]. As a result, the person loses knowledge, stops breathing, and has no palpable palpitation Asystole is considered a medical exigency and requires immediate medical attention: Asystole can do as a progression from other types of cardiac arrhythmias, similar as ventricular fibrillation or pulseless ventricular tachycardia, or it can be a primary event. Underpinning causes of asystole may include severe heart complaint, electrolyte imbalances, medicine toxin, trauma, or other medical conditions [12,13]. Certain threat factors, similar as a history of heart complaint, former cardiac events, and other medical conditions, may increase the threat of asystole. The treatment for asystole is immediate and involves cardiopulmonary reanimation (CPR) to give artificial rotation and advanced cardiac life support (ACLS) measures, including specifics and interventions, to attempt to restore normal heart meter and function, still, the prognostic for asystole is generally poor, and the liability of successful reanimation is low. nonetheless, timely and applicable treatment, along with addressing any underpinning causes, can be pivotal in managing asystole and potentially perfecting issues. It is important to set exigency medical attention incontinently if you suspect someone is pushing asystole or any other form of cardiac arrest. Beforehand recognition, prompt CPR, and ACLS measures are essential in managing asystole and other cardiac extremities [14]. Our coming stop is a high-position check of recent advances in the field of towel engineering, specifically as it relates to cardiac towel engineering and the prospective and being uses of machine literacy [15].




Fig1: Classification of Cardiovascular discovery pipeline

2. Applications of artificial intelligence in cardiology

The use of AI in cardiovascular exploration has soared in the last decade. Among the colourful uses of AI algorithms are opinion, segmentation and reconstruction of images, quality control, prognostics, phenogrouping, and scientific discovery. Cases' meta-data (including demographics and co-morbidities) has been used to train ML models for better delicacy. Artificial intelligence (AI) software widgets and threat assessment systems have also been introduced into cardiology. Specifically, we examine two broad classes of ML-based ways of prognosticating cardiovascular illness [16]. The first approach is to make a machine-literacy model that directly labours the prevalence, mortality, or prognosis of CVDs using clinical follow-up data and threat factors of persons without CVDs or using clinical data and medical imaging of cases with CVDs. Still, it requires a large quantum of patient data for training, and conventional vaticination models are not acceptable for prognosticating the progression of complaints in complex lesions due to the individuality of anatomical, physiological, and functional obstacles faced by each case. The complex case-specific pathogenic processes of CVDs may also be prognosticated by the use of numerical simulations to learn cardiovascular biomechanics. While hemodynamic information (such as haste, pressure, and stress) cannot be picked up from medical images alone, it's possible to determine similar details by combining imaging with patient data and running the data through computational models grounded in the physical principles of circulatory systems. The introductory model and governing equations of the cardiovascular system, as well as unique numerical ways, might be used to increase machine literacy to accelerate the simulation process and deliver customised inflow simulation. Both approaches are essential when trying to determine how common cardiovascular conditions are right [17].

2.1 Electrocardiography

Electrocardiograms (ECGs) are the gold standard for diagnosing cardiac conditions without resorting to invasive procedures. Still, there are cases where doing so is a laborious and time-consuming process. Automated ECG interpretation is now possible because of the wide range of digital ECG equipment. Despite significant advancements, methodical over-reading of electrocardiograms (ECGs) is still advised [18]. Two areas where artificial intelligence (AI) is being employed considerably are automated electrocardiogram (ECG) interpretation and case categorization and prognosis [19]. The treatment for PEA is immediate and involves cardiopulmonary reanimation (CPR) to give artificial rotation and advanced cardiac life support (ACLS) measures, including relating and treating any underpinning causes, administering specifics, and interventions to restore normal heart function [20]. The prognostic for FEA depends on the underpinning cause, and issues can vary. Prompt identification and operation of the underpinning cause, along with timely and applicable CPR and ACLS measures, are pivotal in managing PEA and potentially perfecting issues. It is important to seek exigency medical attention incontinently if you suspect someone is passing PEA or any other form of cardiac arrest. Beforehand recognition, prompt CPR, and ACLS measures are essential in managing PEA and other cardiac extremities [21] Torsade de pointes:

Torsades de pointes are a type of ventricular tachycardia that is characterized by a distinctive twisting pattern on an electrocardiogram (ECG). It can cause a rapid, irregular heartbeat that may degenerate into VF and result in cardiac arrest. Torsades de pointes (TDP) are a type of cardiac arrhythmia characterized by a distinct pattern of rapid-fire, irregular QRS complexes that appear to twist around the baseline of an electrocardiogram (ECG). TDP is a form of ventricular tachycardia, which is an abnormal heart rate that originates in the ventricles (the lower chambers) of the heart. The name "torsades de pointes" is deduced from the French word for "twisting of the points," which refers to the unique appearance of the ECG pattern. TDP is generally characterized by a prolonged QT interval on the ECG, which is the time between the start of the QRS complex and the end of the T wave. Extension of the QT interval can disrupt the normal electrical signals in the heart and lead to the development of TDP. TDP can be caused by various factors, including certain medications, electrolyte imbalances (similar to low potassium or magnesium situations), inheritable factors, heart disease, and other medical conditions [22]. Certain risk factors, similar to a history of long QT syndrome (an inheritable condition that affects the electrical conduction of the heart) or previous occurrences of TDP, may increase the risk of developing TDP. TDP can be a life-changing condition as it can deteriorate into ventricular fibrillation, a more severe and potentially fatal arrhythmia. Symptoms of TDP may include palpitations, dizziness, lightheadedness, fainting, or unexpected loss of consciousness. However, TDP can lead to cardiac arrest and requires immediate medical attention, if left untreated. The treatment for TDP involves identifying and addressing any underlying causes, discontinuing medications that may trigger the arrhythmia, correcting electrolyte imbalances, and managing any other medical conditions. In some cases, interventions similar to intravenous medications or electrical cardioversion may be needed to restore normal heart rate. Long-term management may involve avoiding triggers, taking medications to help prevent recurrences, and close monitoring by a healthcare professional. Still, it is important to seek emergency medical attention instantly, if you suspect someone is having TDP or any other abnormal heart rate. Prompt recognition, appropriate treatment, and addressing underlying causes are critical in managing TDP and preventing complications [23]. It is important to note that these types of cardiac arrest can occur due to various underlying causes, such as heart disease, electrolyte imbalances, drug toxicity, trauma, or other medical conditions. Prompt recognition and appropriate treatment are critical in managing cardiac arrest and improving outcomes. If you suspect someone is experiencing cardiac arrest, it is essential to seek emergency medical attention immediately (13). Drugs of arrest rhythm Adrenaline, often called epinephrine, is a neurotransmitter and hormone generated by way of the adrenal glands in response to pressure or peril. It is a detail of the "fight or flight" physiological reaction, which readies the body for action in the face of a perceived problem. Epinephrine increases coronary heart rate, expands blood vessels, dilates airways, and increases blood sugar levels through stimulating glycogen breakdown in the liver. These actions serve as a manner to prepare the body for movement and insure both muscle tissue and the mind have enough oxygen and nutrients under stressful conditions. Epinephrine is likewise used to deal with severe allergic responses (anaphylaxis), cardiac arrest, and other illnesses. Whilst administered as a drug, epinephrine is usually given through injection [24].

3. Prediction of Cardiovascular Morbidity or Mortality

The lengthy incubation ages and complicated pathogenic mechanisms of cardiovascular complaints are to blame for the failure of early discovery and remedy. In order to produce a threat assessment system for CVDs, data booby-trapping the fine connection between colourful threat factors, and their impact may be necessary [25]. For cardiovascular complaints of vaticination, the gold standard is the Framingham Threat Score (FRS). Using the stoner's cholesterol and non-cholesterol threat variables, it prognosticated the risk of acquiring cardiovascular and cerebrovascular problems over the coming decade. Traditional threat vaticination styles include the Atherosclerosis Cardiovascular Disease (ASCVD) and the Methodical Coronary Threat Evaluation Score (SCORE). Multiple cardiovascular complaint threat factors were studied, leading to the development of multiple vaticination labels. By using AI-based ways to treat CVDs, the forenamed vaticination models were suitable to boost their delicacy and speed of complaint opinion, enabling croakers to identify cases with varied threat layers in advance and further diminish the circumstance of mortality and adverse events. The ML- grounded model has been compared against the assiduity standard for threat vaticination in a number of studies [26].

3.1 Transthoracic echocardiography

The effectiveness and vacuity of echocardiography set it apart piecemeal. As an individual tool, it provides immediate visualisation of the heart's structure, allowing for rapid-fire opinions of structural abnormalities [27]. Due to AI's capability to exclude mortal mistakes and give data that's too subtle for a mortal bystander to pick up on their own, picture measures may be made with lesser perfection. ML algorithms have been extensively used in the field of transthoracic echocardiography to help in picture-based opinion, image segmentation, and prognostication [28]. An innovative system for calculating LVEF automatically from 2-D echocardiographic film using AI-learn pattern recognition is harmonious with the results of the conventional homemade estimate (Biplane Simpson's system) and has a lower change than visual EF. The practicality of using machine learning-enabled computer vision software(AutoLV) to measure left ventricular volumes, ejection fragments (EFs), and average biplane longitudinal strain (LS) to estimate left ventricular function was studied by a transnational group of experimenters. In 98 of the studies, robotization of the measures was doable, with an average analysis time of 8 seconds per subject [29]. The findings demonstrated the feasibility of a rapid-fire and accurate assessment of LVEF and LS. In another corner publication, experimenters use ML styles to automate the clinical interpretation of echocardiograms. A convolutional neural network (CNN) was trained and tested using 14,035 echocardiograms and 70,000 pre-processed images to distinguish 23 shoes and separate the heart chambers across five common views [30]. The VGG network CNN used 10 complication layers, 5 maximum-pool layers, and 3 completely linked layers, and it used a fixed-size grayscale image as input. The data was also put into a 23-way softmax subcast to account for the different perspectives used in echocardiography. Ten frames are taken at random from each echocardiographic movie and used as training data [31]. In a comparison of eleven internal thickness criteria, computerised measures were shown to be superior to mortal bone. In another study, a convolutional neural network (CNN) was trained and validated using annotated still images and videos to classify 15 commonly used echocardiography views. Including the softmax classifier and two completely connected layers, the CNN consists of six convolutional layers. The programme had a 97.8 percent success rate in classifying 12 unique videotape shoes during testing [32].

The technology outperformed board-certified echocardiographers (91.7 vs. 70.2-84, independently) in terms of delicacy over 15 views on single low-resolution images. Using clinical data from conventional echocardiography and features from patch shadowing echocardiography, ML algorithms were designed to distinguish between constrictive pericarditis and restrictive cardiomyopathy [33]. With an AUC of 89.2, the associative memory classifier (AMC) outperformed the competition. Despite their parallels, this system was shown to be more successful than the use of generally used echocardiographic criteria in differentiating between these ailments [34]. The same three machine learning (ML) algorithms (support vector machine, arbitrary timber, and multilayer perceptron with back propagation) were used in an ensemble ML algorithm model to automatically distinguish between HCM and physiological hypertrophy in athletes using patch-tracking echocardiographic data [35]. When compared to constantly used individual factors, the model was shown to have less perceptivity and particularity. Valvular illness might potentially be diagnosed with the use of AI as well. SVM classifiers were used to classify individuals and estimate the inflexibility of their mitral regurgitation (MR), a common stopcock complaint [36]. The system's perceptivity to MR inflexibility in healthy people was 99.38 percent, and its particularity was 99.63 percent. The most current AI advancement in echocardiography is a DL algorithm that can assay videotape, and it has formerly surpassed mortal professionals in EF estimation, cardiomyopathy assessment, and left ventricular segmentation [37]. The algorithm's trip in making prognostications is similar to or lower than that of mortal experts' evaluations of cardiac function. In-depth, deep literacy approach, Echo Net-Dynamic The apical four-chamber image of traditional echocardiogram recordings is used as input. Spatial-temporal complications with residual connections are used to read the EF of each cardiac cycle [38]. Produce left ventricular semantic segmentations at the frame position with little guidance from mortal dogging experts. Based on these findings, the EF and the presence of HF with reduced EF (through AUC) may be prognosticated from beat to beat. The model that formed Echo Net-Dynamic was trained using 130 apical 4-chamber echocardiogram images [39]. As the first videotape-based DL model for echocardiography, it outperforms former DL models when assessing EF. The lowest variations in EF may be detected, allowing for a more precise and prompt discovery of a cardiovascular complaint [40].

4. Cardiac computed tomography angiography

In the battle against coronary artery disease complaint (CAD), prognosticating the probability of Un high threat (CACS born cardiovascular events is critical. Traditional vaticination models he problems with disagreement in confirmation cohorts, a dearth of applicable data, and a small pool of predictors [41]. Recent advances in AI, coupled with the need for robust vaticination tools, have led to the ML-based of ML-grounded threat vaticination moderate against coronary artery disease (CAD), prognosticating the probability of unborn cardiovascular events is critical. Traditional vaticination models have problems with disagreement in confirmation cohorts, a dearth of applicable data, and a small pool of predictors. Recent advances in AI, coupled with the need for robust vaticination tools, have led to the development of ML-based threat vaticination models (81). Coronary roadway complaint Romary roadway frequency (CAD related prognosis lateprognostigreatly improved bygone bettered Beynon computed cardiac reckoned tomography angiography (CTA), which permits direct assessments of coronary roadway patency [42]. Stenosis of an atherosclerotic lesion may be detected by A, and coronary roadway calcium scoring (CACS) can be used to assess atherosclerosis

subjectively and quantitatively with or without CTA [43]. through bracketed threat bracket and optic born formation brit methods images, ML ways are used b CTAs to enhance individual Delica and pr Ostic issues [44]. A score attained using a boosted ensemble algorithm for threat position using data from a multicentered amuletic-center registry was compared to the AU of standard CTA threat evaluation follow-r a of 4.61.5llow- up of4.61.5 times, t-based the ML grouped fashion was compared totally danced than the former CTA threat assessments, Demontra ameliorate the may ameliorate threat Barlage-n another large- scale study, 13,054 cases the suspected or verified CAD had their CACS assessed. The CACS another clinical threat pointer was into a grade boosting ML algorithm (XG tree-grounding tree- grounded ensemble approach) to see whether they may ameliorate threat categorization [45]. The stud predictor prognosticates the threat of obstructive CAD before testing was increased by around 9 percent when CACS was included in the birth model. This increased to around 1 in the group of young younger (those youngish the 65). In another disquisition delved into indenters delved whether or not it would be possible to use ML to risk stratify a symptom-fertigation [46]. An aggregate individual's individualities had CTA reviews using CACS, with acclimatizers to acclimate. An ML algo them was used o prognosticate issues for ca (CAC Seth moderate (CACS> 100) and high- threat (CACS> 400) CAD, and the results were compared to those attained using a conventional threat vaticination score [47]. Only 2.4 of people had suggestions for high-threat CAD, but 8.4 had suggestions for moderate CAD. In the study, the ML algorithm was shown to be superior to the conventional threat vaticination score for both moderate- and high-threat CAD cases. When applied to CAD vaticination, ML improves clinical issues by automating and perfecting the selection process for further individual evaluation of the applicable campaigners; it also reduces radiation exposure; and it allows for a more precise threat position (exploring all available information to calculate each existing threat) [48]. Better threat position models might be produced using ML to prognosticate CAD issues, which would save both time and money in clinical settings. Motwani et al. conducted a worldwide multicenter study in which 10,300 individuals with suspected CAD were covered five times. Each case had a CTA when medically indicated [49]. Twenty-five clinical parameters and forty-four CTA parameters were recorded. Modelling was carried out using a boosted ensemble fashion (Logit Boost), and cross-validation was performed using a 10-fold stratified design. The primary outgrowth measure for this exploration was each-beget mortality (ACM). Seven hundred forty-five cases failed throughout the five-day observation period [50]. The ML approach is a more accurate predictor of a 5-time ACM, as shown by its AUC, which was significantly higher than that of the clinical or CTA data alone. Acute coronary syndrome (ACS) is most frequently caused by atherosclerotic pillars that are unstable but not obstructive [51]. Coronary roadway stenosis and stress-induced myocardial ischemia may be diagnosed without invasive procedures, but these unstable non-obstructive pillars cannot. There are several threat factors that can increase the liability of passing a car arrest. Some of the common threat factors for cardiac arrest include Age The threat of cardiac arrest increases with age, and the maturity of cardiac apprehensions do in individualities over the age of 45 [52]. Gender Men are at an advanced threat of cardiac arrest compared to men, although the threat for women increases after menopause family history. Having a family history of cardiac arrest or unforeseen cardiac death can increase the threat of passing a cardiac arrest. Coronary roadway complaint (CAD) CAD is a condition where the highways that supply blood to the heart muscle come narrowed due to the figure-up of shrine [53]. CAD is a major threat factor for cardiac arrest. former heart attack individualities who have preliminarily endured a heart attack are at

an increased threat of cardiac arrest. Arrhythmias Certain types of arrhythmias, similar as ventricular fibrillation, can increase the threat of cardiac arrest [54,55]. Cardiomyopathy Cardio myopathy is a condition that affects the heart muscle and can increase the threat of cardiac arrest. medicine or alcohol abuse Substance abuse, including inordinate alcohol consumption or lawless medicine use, can increase the threat of cardiac arrest. Smoking cigarettes increases the threat of cardiac arrest by damaging the blood vessels and contributing to the development of shrine in the highways, rotundity Being fat or fat carrease the threat of cardiac arrest due to its association with other threat factors similar as high blood pressure, high cholesterol, and diabetes High blood pressure unbridled high blood pressure hypertension) is a significant threat factor for cardiac arrest [34]. High cholesterol High situations of LDL (low viscosity lipoprotein) cholesterol, generally known as bad cholesterol, can contribute to the development of shrine in the highways, adding the threat of cardiac arrest. Diabetes Having diabetes, particularly inadequately controlled diabetes, can increase the threat of cardiac arrest. Sedentary life Lack of regular physical exertion and a sedentary life can increase the threat of cardiac arrest. it is important to note that having one or further of these threat factors does not inescapably mean that an existent will witness a cardiac arrest. still, having multiple threat factors can significantly increase the overall threat it is essential to be apprehensive of these threat factors and take way to manage them through life changes, medical operation, and regular check-ups with a healthcare professional to reduce the threat of cardiac arrest and promote heart health [56].

5. Gene mutants in human cardiac failure

Statistical studies demonstrate that heritable factors and inheritable variations contribute to the development of numerous forms of cardiovascular disease (CVD). KCNH2 (LQT2) missense mutations (T983I) are significantly linked to arrhythmogenic conditions wis aits similar QT pattern [57]. Induced pluripotent stem cell (iPSC) and Gen editing styles allow mole Cur-position intervention card tissue engineering for cell adhesion, isolation, and cell alignment [58]. With the help of genome editing with programmable nucleases using clustered regularly interspaced short systems (CRISPR) and Caspase 9 (Cas9) as guiding enzymes, a mutation in the cardiac ryanodine receptor 2(RYR2) gene associated with catecholaminergic polymorphic ventricular tachycardia type 1(CPVT1) was introduced into piscine discrepancies/Cas9-s9-generaR453C-3C- MHC and cases whose PRKAG2 mutations repaired, CRISPR/Cas9SCas9(69) have recovered physiological mitochondrial functions, electrophysiological abnormalities, and structural abnormalities, suggesting this an respectable strategy to restoring CM exertion [59].

5.2 Potential of CRISPR/Cas systems in cardiac tissue engineering

Homology-directed repair (HDR) or non-homologous end joining (NHEJ) is employed to make new DNA. These methods may be used to create either random or targeted mutations into DNA sequences. Off-target effects and the difficulty of delivering big Cas9 sequences are two of the challenges that must be addressed before this method can be utilised extensively [60]. It is possible for unwanted and incompatible off-target effects to arise when genetic material is transformed using developed programmable nucleases. Reducing the non-specific binding of gRNA sequences may ameliorate these off-target effects in CRISPR/Cas9 systems [61]. To design cells for cardiac tissue regeneration, CRISPR/Cas9 systems may be introduced into cells using plasmid DNA, RNA, or proteins. Recently, Doudna et al. discovered a third platform for RNA-programmed genome editing by studying CasX enzymes that originated from a TnpB-

type transposase. CasX is smaller than Cas9 and Cas12a because it is less active in trans-cleavage and has a higher RNA content but lower protein content [62]. Potential advantages over existing CRISPR/Cas systems include enhanced therapeutic delivery and the avoidance of the body's immunological response. CRISPR/Cas technologies have been proven to be useful for cardiac stem cell engineering in a number of different contexts, including the resuscitation of quiescent cells and terminally differentiated mammalian cells, and the modification of cell architectures on demand to address the development of tissue architecture [63]. Another option may be to change iPSC-derived CMs in situ utilising the CRISPR/Cas9 system, although ex vivo culture of primary CMs may be challenging. These engineered iPSCs may differentiate into cardiac progenitors or CMs, both of which may be administered intracoronarily or intramyocardially to repair a damaged heart. Micro threads have been used to implant iPSC derived CMs into heart tissue and contractile cardiac fibres [64]. However, the structural and functional immaturity of iPSC-derived CMs restricts their application in fields like drug screening and cell-based therapies. One solution is to plan the architecture of the extracellular matrix (ECM) that is required for healthy cell activity and development [65].

1. **Gene Editing:** CRISPR/Cas systems can be used to precisely edit the genome of cells, including cardiac cells, enabling the correction of genetic mutations associated with cardiovascular diseases. By targeting specific genes implicated in cardiac disorders, such as those involved in cardiomyopathies or arrhythmias, CRISPR/Cas can potentially correct the underlying genetic defects and restore normal function [66].
2. **Disease Modeling:** CRISPR/Cas systems can generate disease models by introducing specific genetic mutations into cells or tissues. This approach allows researchers to study the molecular mechanisms underlying cardiac diseases and develop new therapies. For instance, by introducing disease-causing mutations into pluripotent stem cells, researchers can differentiate them into cardiomyocytes and study how the mutations affect cardiac function [67].
3. **Cell Line Engineering:** CRISPR/Cas can be used to modify cell lines used in cardiac tissue engineering to improve their functionality and therapeutic potential. For example, researchers can use CRISPR/Cas to enhance the proliferation or differentiation capacity of cardiac progenitor cells or induced pluripotent stem cells (iPSCs), leading to improved tissue engineering outcomes [68].
4. **Engineering Designer Cells:** CRISPR/Cas systems can enable the engineering of cells with specific characteristics that are desirable for cardiac tissue engineering. For instance, researchers can use CRISPR/Cas to modify cells to enhance their regenerative potential, improve their integration within host tissues, or increase their resistance to immune rejection [69].
5. **Epigenetic Modifications:** CRISPR/Cas-based tools, such as dCas9 (catalytically inactive Cas9), can be used to target and modify epigenetic marks on the genome. Epigenetic modifications play a crucial role in cardiac development and disease. By precisely modulating epigenetic marks, researchers can potentially direct the differentiation of stem cells into cardiomyocytes or reprogram mature cells into a cardiac lineage, aiding in the generation of functional cardiac tissue [70].
6. **Drug Discovery:** CRISPR/Cas systems can facilitate drug discovery for cardiac diseases by enabling the systematic screening of genes and their functional roles in cellular models. This approach can help identify novel therapeutic targets and accelerate the development of new treatments for cardiac disorders [71].




Fig2: Mechanism of Stem Cell Differentiation

6. Stem cell differentiation

Differentiation of stem-cell-derived CMs into the desired lineages is dependent on several variables, including scaffold architecture, cell fate, and the cell's surroundings [72]. The differentiation of hiPSCs into mature CMs has been proposed as a potential tool for cardiac tissue creation treatment. Foetal hiPSCs have the potential to provide almost pure CMs after isolation. However, human ESC-derived CMs still lack many desirable characteristics, such as proper distribution and organisation and the presence of functioning transverse tubules (T-tubules) despite being shown to be a reliable source of adult human cardiac myocyte for clinical treatments [73]. Mature human ESC-derived CMs may replace immature ones to reduce the risk of arrhythmias in transplantation therapy, as reported by Chong et al. The various applications of adult-like hiPSC-derived CMS include drug toxicity assessment and stem cell-based disease models. There are reported ways for making cardiac tissue using CMs produced from stem cells [74]. These CMs have a cellular morphology that is consistent with that of the adult human heart. Ronaldson-Bouchard et al co-cultured hiPSC-derived CMs with fibroblasts in a fibrin-based hydrogel to generate mature cardiac tissues around two bendable pillars [75]. These pillars were used to create stresses in the contracting tissues, which were similar to those seen in real myocardium [76]. Following 1 week in culture, hiPSCs were able to differentiate and grow into mature CMs when subjected to either constant electrical stimulation (2 Hz for 3 weeks) or intensity training (2 to 6 Hz ramp over 2 weeks, then back to 2 Hz for one week). Molecular maturity was shown by the presence of adult-like conduction, a ventricular isoform of myosin linked to the atrial isoform, enhanced ATP production, and the capacity to transport calcium [77]. Cellular analysis revealed that CMs with well-organized sarcomeres and many mitochondria were expanding [78]. It has been shown that T-tubules and the folding of the sarcolemma membrane are required for proper calcium transport in the cell. Cells in tissue architectures improved their ability to transmit and receive electrical impulses by physically

attaching to one another at gap junctions. Human ventricular cardiac anisotropic sheet CMs produced from hiPSCs that are properly aligned have been discovered to possess key electrical features of the original human ventricle [79]. Only after extensive pre-training of hiPSC-CMs was this seen. Cardiac tissues improved their ability to execute action potentials by coupling excitation and contraction after extensive training. Mechanical contraction of the myocardium follows electrical stimulation (excitation) of the heart muscle. Wiegerinck et al [80]. discovered that increased beating frequency was due equally to both stronger contractions and faster relaxation. Success in generating CMs from hiPSCs has been demonstrated to be most likely in response to a combination of hormone-driven signals, intense electrical stimulation cell composition and matrix/media, and other regulatory factors [81].

Biodegradable, mildly immunogenic natural polymer scaffolds play a significant role in cardiac tissue engineering by promoting the differentiation and growth of hiPSC-derived CMs. Using a fibrin and collagen scaffold, Kaiser et al. developed synthetic myocardium from hiPSC-derived CMs [82]. Expression of cardiac troponin T (cTnT) was shown to vary with scaffold density in CM populations. Maximum density suggested a 40-50% cTnT+ population, with both low density (24.4% cTnT+ CM purities) and high density (60.2% cTnT+ CM purities) expressing positively. Determining the connection between hiPSC-derived CMs and scaffold interactions, this study lays the groundwork for the integrated design of personalised scaffold architectures in cardiac tissue engineering [83].

7. Limitations of AI-Based Technologies

Overly optimistic assumptions about artificial intelligence (AI) and related subjects have contributed to the possibility of disappointment. Experts have noted that "ML is a natural extension of traditional approaches, not a magical device that can spin data into gold" proving that it is not a panacea for data analysis [84]. The results of ML are not always superior to the results of traditional analytic methods and the converse is also true. Many ML algorithms, for instance, did not outperform traditional prediction models in predicting 30-day readmissions for heart failure, as found by Frizzell et al. It is crucial to remember that "as more control is ceded to algorithms, it is important to note that these new algorithmic decision-making tools come with no guarantees of fairness, equitability, or even veracity" [85]. When applying ML/DL to new datasets, there are three common sorts of issues that might arise: First, there are issues with data integrity (a new spin on the old adage "garbage in, garbage out"); second, there is a lack of variety in training datasets; and third, there is a limited or non-existent capacity to review for methodological bias in analysis [86]. The "black box" nature of neural networks makes this second concern all the more pressing. The automated nature of a neural network allows for the discovery of previously unsuspected patterns, but human scientists have little room for error when attempting to assess the computer's justifications for its conclusions [87]. It is incumbent upon human clinicians to make clinically relevant interpretations of the data and to critically evaluate the AI's predictions. Large, well curated datasets are required for training DL algorithms to provide diagnostic and predictive abilities. However, a lack of comprehensive databases of thoroughly annotated photos and videos has hampered several areas of medicine, including IC. To help train deep neural networks, however, generative adversarial networks (GANs) have been used to generate high-resolution image datasets such as angiograms and echocardiograms [88].

8. Challenges and Future Prospects

The persistent advancement of artificial intelligence and its usage in the medical arena has led to revolutionary changes in medical practises. If ML-based models can improve upon the gold standard method for predicting CVD morbidity and death, then we may need to reevaluate our methods. New ideas, methods, and research paradigms might emerge from the use of ML models to biomechanical modelling [89]. However, there are some problems that should be fixed. (1) Early CVD prediction in a database is predicated on the presence of both large datasets and high-quality data. It takes a lot of computing power to do high-precision mechanical calculations, and it's not easy to get data on rare diseases. Concerns about privacy and ethics extend to the possible applications of medical data [90]. This highlights the significance of sourcing higher-quality datasets and doing training and optimisation on manageable sample sizes. Researchers in the field of artificial intelligence require quick and simple access to high-quality data kept in private locations [91]. Research has revealed that AI-based models have more reliability and consistency than traditional prediction models. Additional testing with large pathological datasets is necessary to validate the efficacy and stability of the proposed approach and the results from single-center studies need to be corroborated by those from multi-center studies using even larger data sets before the models can be used clinically. Three-fold Generalization Predictions of CVDs have been made using ML models with some success in recent years [92]. The ability of AI-based prediction models to generalise to new data for specific patients is still a work in progress. For instance, ML-based models struggle to adequately reflect the many intricate 3D morphologies of each cardiovascular disease in patient-specific biomechanical applications. In order to develop a broadly applicable machine learning-based prediction model, it may be essential to learn large physiologically plausible datasets [93]. A fourth defining feature: It is still difficult to characterise the thought process underlying individual judgements, despite the high anticipated accuracy of artificial intelligence in healthcare [94]. The "black box" nature of machine learning has left researchers with more questions than solutions in the past [95]. Complexity of models and subjective evaluation criteria both play a role in the development and evaluation of AI models. The explainable AI model has been trending for a while [96], but it hasn't yielded the best results, and there isn't a standardised way to evaluate it yet. In addition, the ability to explain model findings takes a back seat to the model's predictive strength. Researchers in the future will need to use a standardised and repeatable research method to evaluate the explainability of AI-based prediction models [97].

Though AI has made great strides in the last few decades, more research and development is needed to improve the model's accuracy, robustness, generalizability, and explainability. One potential future trend and development route in healthcare is the use of artificial intelligence (AI), which has the potential to both improve the quality and cost-effectiveness of medical treatment and reduce some of the accompanying burdens [98]. Allopathic Approach: The allopathic approach, also known as conventional or Western medicine, is based on the scientific method and emphasizes the diagnosis and treatment of disease symptoms using pharmaceuticals, surgery, and other interventions. Traditional Approach: The traditional approach, often referred to as alternative, complementary, or holistic medicine, is based on a holistic view of health that considers the body, mind, and spirit as interconnected and seeks to

restore balance and harmony to achieve health and wellness. It often utilizes natural remedies, lifestyle modifications, and other non- conventional therapies.

Allopathic Approach: Allopathic medicine relies heavily on laboratory tests, imaging studies, and other modern diagnostic tools to identify diseases and conditions. It often focuses on identifying specific disease markers and treating them with targeted interventions.

Traditional Approach: Traditional approaches may use a combination of diagnostic methods, including observing physical signs, assessing symptoms, taking a detailed medical history, and using traditional diagnostic techniques such as pulse diagnosis, tongue examination, and other non-invasive methods. Traditional practitioners often consider the overall health and well-being of the individual and may also consider environmental and social factors.

Allopathic Approach: Allopathic medicine typically uses pharmaceuticals, surgeries, radiation, and other interventions to treat diseases and conditions. It often focuses on managing symptoms and addressing the underlying disease process using evidence-based Interventions.

Traditional Approach: Traditional approaches may use a wide range of treatment modalities depending on the system of traditional medicine being practiced. These may include herbal remedies, acupuncture, massage, dietary and lifestyle modifications, energy therapies, mind-body techniques, and other holistic approaches that aim to support the body's natural healing mechanisms and restore balance.

Allopathic Approach: The allopathic approach often focuses on treating diseases and conditions once they have occurred, with an emphasis on managing symptoms and using Interventions such as medications and surgeries to eliminate or control the disease process.

Traditional Approach: The traditional approach often places a strong emphasis on prevention and maintaining overall health and wellness through lifestyle modifications, dietary guidelines, and other holistic practices. Traditional systems of medicine may also focus on identifying and addressing the root causes of illness, rather than just treating symptoms.

9. Regulation and Evidence

Allopathic Approach: Allopathic medicine is typically regulated by government bodies and follows a rigorous process of evidence-based research, clinical trials, and regulatory approval before interventions are widely used in clinical practice.

Traditional Approach: Traditional approaches to medicine vary widely in terms of regulation and evidence. Some traditional systems of medicine, such as Traditional Chinese Medicine and Ayurveda, have a long history of documented use and may have their own regulatory frameworks, while others may not have standardized guidelines or may rely on traditional knowledge and practices without extensive scientific evidence.

Integration with Conventional Medicine.

Allopathic Approach: Allopathic medicine is often the dominant form of healthcare in many countries and is typically integrated into mainstream healthcare systems, with conventional medical treatments being the primary form of intervention.

Traditional Approach: Traditional approaches may be used as complementary or alternative therapies alongside conventional medicine, and some traditional practices, such as acupuncture or chiropractic, are integrated into mainstream healthcare systems in some countries. However, the level of integration and acceptance of traditional approaches may vary widely depending on cultural, geographic, and regulatory factors.

10. Conclusion

Necrosis, apoptosis, and onychosis are linked to heart failure, making the heart an attractive research subject for tissue engineers. Stem cell transplantation is a popular technique for cardiac treatment, but histocompatibility issues have hampered stem cell-based treatments. Heart repair using immunological tolerance and stem cell growth is an emerging area of study [99]. AI has been used to develop algorithms that can sift through large quantities of data in search of recreating patterns that can be used to make prognostications about the future. Machine literacy (ML) is used to develop algorithms that can sift through large quantities of data in hunt of recreating patterns that can be used to make prognostications about the future. Deep literacy (DL) is used to reuse network [100].

Allopathic drug, generally known as conventional or Western drug, is a medical system that is considerably rehearsed and recognised around the world it is innovated on scientific data and frequently employs specifics, surgery, and other procedures to cure ails and palliate symptoms. Traditional approaches to drug, on the other hand, relate to medical systems that are constantly innovated on artistic or literal practises and are not inescapably supported by scientific data [101]. Then are some important distinctions between allopathic and traditional healthcare approaches substantiation- grounded. anecdotal to demonstrate the safety and efficacy of curatives, allopathic drug depends on scientific exploration and clinical trials. Traditional ways may calculate on anecdotal substantiation, artistic ideas, or literal practises that are not inescapably backed up by rigorous scientific exploration [102]. Allopathic drug frequently employs a methodical approach to illness opinion and treatment grounded on established principles and protocols. Traditional ways may employ colourful individual procedures, similar as palpitation opinion or lingo examination, as well as a variety of treatments, similar as herbal drugs, salutary adaptations, acupuncture, or other indispensable curatives. Allopathic drug adheres to a methodical system of medical education and training. with controlled licence and professional morals. Traditional ways may not inescapably have invariant training or nonsupervisory control, performing in interpreters with different degrees of experience and quality of treatment [103]. Allopathic drug is constantly integrated into ultramodern healthcare systems with established hospitals, conventions, and healthcare installations. Traditional ways may be regarded supplementary or indispensable to allopathic drug, and they may be utilised in addition to or rather of contemporary medical treatments. Approach to acute and exigency care with bettered medical tools and ways, allopathic drug is frequently well equipped to address acute and exigency medical extremities similar as trauma, cardiac arrest, or other life changing diseases. Traditional means of dealing with acute medical extremities may not always have the same degree of movie or coffers [104]. Differences in culture and gospel Traditional styles to drug may be explosively rooted in artistic or philosophical ideas and may have a holistic perspective of health that considers variables similar as mind, body, and spirit. Allopathic drug takes a reductionist approach to treatment. fastening on individual symptoms or ails. Treatment safety and regulation Before being certified for clinical use, allopathic drug is typically subordinated to expansive testing for safety and efficacy. Traditional ways may have variable degrees of safety and regulation, and certain herbal drugs or indispensable curatives may pose pitfalls of side goods or medicine relations. it is pivotal to flash back that both allopathic and traditional styles to drug have advantages and disadvantages, and the choice of healthcare strategy may be told by preferences, artistic beliefs, and the specific disease being treated. Working with professed healthcare experts, anyhow of system, is critical to icing safe and effective care. Integrative drug, which incorporates factors of both allopathic and

traditional treatments, is a new area that aims to give a comprehensive and patient-centred approach to healthcare. Allopathic and traditional approaches are two different paradigms of healthcare that have distinct differences in their philosophy, diagnostic methods, treatment modalities, and overall approach to managing health and illness. Here is a comparison of some key aspects between allopathic and traditional approaches [105]

Traditional vaticination models have problems with disagreement in confirmation cohorts, a dearth of applicable data, and a small pool of predictors. Recent advances in AI, coupled with the need for robust vaticination tools, have led to the development of ML-based threat vaticination models. Coronary roadway calcium scoring (CACS) can be used to assess atherosclerosis subjectively and quantitatively with or without CTA. A score attained using a boosted ensemble algorithm for threat position was compared to the AU of standard CTA threat evaluation follow-up of 4.61.5 times. In another study, 13,054 cases the suspected or verified CAD had their CACS assessed [106].

References

1. Heallen TR, Martin JF. Heart repair via cardiomyocyte-secreted vesicles. *Nat Biomed Eng.* 2018;2(5):271. doi: 10.1038/s41551-018-0239-5.
2. Mohamed TMA, Ang YS, Radzinsky E, Zhou P, Huang Y, Elfenbein A, Foley A, Magnitsky S, Srivastava D. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. *Cell.* 2018;173(1):104–10+. doi: 10.1016/j.cell.2018.02.014.
3. Zimmer A, Bagchi AK, Vinayak K, Bello-Klein A, Singal PK. Innate immune response in the pathogenesis of heart failure in survivors of myocardial infarction. *Am J Phys Heart Circ Phys.* 2019;316(3):H435–H445.
4. Frangogiannis NG. The functional pluralism of fibroblasts in the infarcted myocardium. *Circ Res.* 2016;119(10):1049–1051. doi: 10.1161/CIRCRESAHA.116.309926.
5. Weerasinghe P, Buja LM. Oncosis: an important non-apoptotic mode of cell death. *Exp Mol Pathol.* 2012;93(3):302–308. doi: 10.1016/j.yexmp.2012.09.018.
6. Tzahor E, Poss KD. Cardiac regeneration strategies: staying young at heart. *Science.* 2017;356(6342):1035–1039. doi: 10.1126/science.aam5894.
7. MEMBERS WG, Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. *Circulation.* 2017;135(10):e146.
8. Dhingra R, Vasan RS. Age as a risk factor. *Med Clin North Am.* 2012;96(1):87–91. doi: 10.1016/j.mna.2011.11.003.
9. Barker Roger A., Carpenter Melissa K., Forbes Stuart, Goldman Steven A., Jamieson Catriona, Murry Charles E., Takahashi Jun, Weir Gordon. The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards? *Stem Cell Reports.* 2018;10(5):1429–1431. doi: 10.1016/j.stemcr.2018.04.010.
10. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: state of the art. *Circ Res.* 2014;114(2):354–367. doi: 10.1161/CIRCRESAHA.114.300522.
11. Bejoy J, Wang Z, Bijonowski B, Yang M, Ma T, Sang Q-X, Li Y. Differential effects of heparin and hyaluronic acid on neural patterning of human induced pluripotent stem cells. *ACS Biomater Sci Eng.* 2018;4(12):4354–4366. doi: 10.1021/acsbiomaterials.8b01142.
12. Shiekh PA, Singh A, Kumar A. Engineering bioinspired antioxidant materials promoting cardiomyocyte functionality and maturation for tissue engineering application. *ACS Appl Mater Interfaces.* 2018;10(4):3260–3273. doi: 10.1021/acscami.7b14777.
13. Zhu Chenghao, Rodda Andrew E., Truong Vinh X., Shi Yue, Zhou Kun, Haynes John M., Wang Bing, Cook Wayne D., Forsythe John S. Increased Cardiomyocyte Alignment and Intracellular Calcium Transients Using Micropatterned and Drug-Releasing Poly(Glycerol Sebacate) Elastomers. *ACS Biomaterials Science & Engineering.* 2018;4(7):2494–2504. doi: 10.1021/acsbiomaterials.8b00084.
14. Chen Kellen, Vigliotti Andrea, Bacca Mattia, McMeeking Robert M., Deshpande Vikram S., Holmes Jeffrey W. Role of boundary conditions in determining cell

- alignment in response to stretch. *Proceedings of the National Academy of Sciences*. 2018;115(5):986–991. doi: 10.1073/pnas.1715059115.
15. Tandon N, Cannizzaro C, Chao P-HG, Maidhof R, Marsano A, Au HTH, Radisic M, Vunjak-Novakovic G. Electrical stimulation systems for cardiac tissue engineering. *Nat Protoc*. 2009;4(2):155. doi: 10.1038/nprot.2008.183.
 16. Stoppel WL, Kaplan DL, Black LD., III Electrical and mechanical stimulation of cardiac cells and tissue constructs. *Adv Drug Deliv Rev*. 2016;96:135–155. doi: 10.1016/j.addr.2015.07.009.
 17. Radisic M, Park H, Chen F, Salazar-Lazzaro JE, Wang Y, Dennis R, Langer R, Freed LE, Vunjak-Novakovic G. Biomimetic approach to cardiac tissue engineering: oxygen carriers and channeled scaffolds. *Tissue Eng*. 2006;12(8):2077–2091. doi: 10.1089/ten.2006.12.2077.
 18. Allegue C, Gil R, Blanco-Verea A, Santori M, Rodríguez-Calvo M, Concheiro L, Carracedo Á, Brion M. Prevalence of HCM and long QT syndrome mutations in young sudden cardiac death-related cases. *Int J Legal Med*. 2011;125(4):565–572. doi: 10.1007/s00414-011-0572-7.
 19. Yamaguchi N, Zhang X-H, Wei H, Morad M. Generation and characterization of CPVT1 cardiomyocytes using human induced pluripotent stem cells and CRISPR/Cas9 gene editing. *Biophys J*. 2018;114(3):116a. doi: 10.1016/j.bpj.2017.11.667.
 20. Tang J, Cui X, Caranasos TG, Hensley MT, Vandergriff AC, Hartanto Y, Shen D, Zhang H, Zhang J, Cheng K. Heart repair using Nanogel-encapsulated human cardiac stem cells in mice and pigs with myocardial infarction. *ACS Nano*. 2017;11(10):9738–9749. doi: 10.1021/acsnano.7b01008.
 21. Wang H, Hao J, Hong CC. Cardiac induction of embryonic stem cells by a small molecule inhibitor of Wnt/ β -catenin signaling. *ACS Chem Biol*. 2011;6(2):192–197. doi: 10.1021/cb100323z.
 22. Chen H, Zhang Y, Ding P, Zhang T, Zan Y, Ni T, Lin R, Liu M, Pei R. Bone marrow-derived mesenchymal stem cells encapsulated in functionalized Gellan gum/collagen hydrogel for effective vascularization. *ACS Appl Bio Mater*. 2018;1(5):1408–1415. doi: 10.1021/acsabm.8b00361.
 23. Chetty SS, Praneetha S, Govarathanan K, Verma RS, Vadivel Murugan A. Noninvasive tracking and regenerative capabilities of transplanted human umbilical cord-derived mesenchymal stem cells labeled with I-III-IV semiconducting nanocrystals in liver-injured living mice. *ACS Appl Mater Interfaces*. 2019;11(9):8763–8778. doi: 10.1021/acсами.8b19953.
 24. Banerjee Monisha N., Bolli Roberto, Hare Joshua M. Clinical Studies of Cell Therapy in Cardiovascular Medicine. *Circulation Research*. 2018;123(2):266–287. doi: 10.1161/CIRCRESAHA.118.311217.
 25. Poulos J. The limited application of stem cells in medicine: a review. *Stem Cell Res Ther*. 2018;9(1):1–1. doi: 10.1186/s13287-017-0735-7.
 26. Martin I, Galipeau J, Kessler C, Le Blanc K, Dazzi F. Challenges for mesenchymal stromal cell therapies. *Sci Transl Med*. 2019;11(480):aat2189. doi: 10.1126/scitranslmed.aat2189.
 27. Kretzschmar K, Post Y, Bannier-Hélaouët M, Mattiotti A, Drost J, Basak O, Li VSW, van den Born M, Gunst QD, Versteeg D, et al. Profiling proliferative cells and their

- progeny in damaged murine hearts. *Proc Natl Acad Sci*. 2018;115(52):E12245–E12254. doi: 10.1073/pnas.1805829115.
28. van Berlo JH, Molkentin JD. An emerging consensus on cardiac regeneration. *Nat Med*. 2014;20:1386. doi: 10.1038/nm.3764.
 29. Vicinanza C, Aquila I, Cianflone E, Scalise M, Marino F, Mancuso T, Fumagalli F, Giovannone ED, Cristiano F, Iaccino E, et al. Kitcre knock-in mice fail to fate-map cardiac stem cells. *Nature*. 2018;555:E1. doi: 10.1038/nature25771.
 30. Lee RT. Adult cardiac stem cell concept and the process of science. *Circulation*. 2018;138(25):2940–2942. doi: 10.1161/CIRCULATIONAHA.118.036407.1
 31. Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, Henning BJ, Stirparo GG, Papait R, Scarfo M, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. *Cell*. 2013;154(4):827–842. doi: 10.1016/j.cell.2013.07.039.
 32. Li Y, He LJ, Huang XZ, Bhaloo SI, Zhao H, Zhang SH, Pu WJ, Tian XY, Li Y, Liu QZ, et al. Genetic lineage tracing of nonmyocyte population by dual recombinases. *Circulation*. 2018;138(8):793–805. doi: 10.1161/CIRCULATIONAHA.118.034250.
 33. Vicinanza C, Aquila I, Scalise M, Cristiano F, Marino F, Cianflone E, Mancuso T, Marotta P, Sacco W, Lewis FC, et al. Adult cardiac stem cells are multipotent and robustly myogenic: c-kit expression is necessary but not sufficient for their identification. *Cell Death Differ*. 2017;24:2101. doi: 10.1038/cdd.2017.130.
 34. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA, et al. Revisiting cardiac cellular composition. *Circ Res*. 2016;118(3):400–409. doi: 10.1161/CIRCRESAHA.115.307778.
 35. Song H-HG, Rumma RT, Ozaki CK, Edelman ER, Chen CS. Vascular tissue engineering: progress, challenges, and clinical promise. *Cell Stem Cell*. 2018;22(3):340–354. doi: 10.1016/j.stem.2018.02.009.
 36. Richards DJ, Tan Y, Coyle R, Li Y, Xu R, Yeung N, Parker A, Menick DR, Tian B, Mei Y. Nanowires and electrical stimulation synergistically improve functions of hiPSC cardiac spheroids. *Nano Lett*. 2016;16(7):4670–4678. doi: 10.1021/acs.nanolett.6b02093.
 37. Au - Llucià-Valldeperas A, Au - Bragós R, Au - Bayés-Genís A. Simultaneous electrical and mechanical stimulation to enhance Cells' Cardiomyogenic potential. *JoVE*. 2019;(143):e58934. 10.3791/58934.
 38. Miotto Riccardo, Wang Fei, Wang Shuang, Jiang Xiaoqian, Dudley Joel T. Deep learning for healthcare: review, opportunities and challenges. *Briefings in Bioinformatics*. 2017;19(6):1236–1246. doi: 10.1093/bib/bbx044.
 39. Soni J, Ansari U, Sharma D, Soni S. Predictive data mining for medical diagnosis: An overview of heart disease prediction. *Int J Comput Appl*. 2011;17(8):43–48.
 40. Jo Areum, Ham Sangwoo, Lee Gum Hwa, Lee Yun-Il, Kim SangSeong, Lee Yun-Song, Shin Joo-Ho, Lee Yunjong. Efficient Mitochondrial Genome Editing by CRISPR/Cas9. *BioMed Research International*. 2015;2015:1–10. doi: 10.1155/2015/305716
 41. Lee EK, Tran DD, Keung W, Chan P, Wong G, Chan CW, Costa KD, Li RA, Khine M. Machine learning of human pluripotent stem cell-derived engineered cardiac tissue

- contractility for automated drug classification. *Stem Cell Rep.* 2017;9(5):1560–1572. doi: 10.1016/j.stemcr.2017.09.008.
42. Ballester PJ, Mitchell JB. A machine learning approach to predicting protein–ligand binding affinity with applications to molecular docking. *Bioinformatics.* 2010;26(9):1169–1175. doi: 10.1093/bioinformatics/btq112.
 43. Komura D, Ishikawa S. Machine learning methods for histopathological image analysis. *Comput Struct Biotechnol J.* 2018;16:34–42. doi: 10.1016/j.csbj.2018.01.001.
 44. Rahmani-Monfared K, Fathi A, Mozaffari A, Rabiee SM. Application of self-learning evolutionary algorithm for optimal design of a porous polymethylmethacrylate scaffold fabricated by laser drilling process. *Proc Inst Mech Eng E.* 2013;227(3):211–224. doi: 10.1177/0954408912459302.
 45. Suhaeri M, Subbiah R, Kim S-H, Kim C-H, Oh SJ, Kim S-H, Park K. Novel platform of cardiomyocyte culture and coculture via fibroblast-derived matrix-coupled aligned electrospun nanofiber. *ACS Appl Mater Interfaces.* 2016;9(1):224–235. doi: 10.1021/acsami.6b14020
 46. Cui X, Tang J, Hartanto Y, Zhang J, Bi J, Dai S, Qiao SZ, Cheng K, Zhang H. NIPAM-based microgel microenvironment regulates the therapeutic function of cardiac stromal cells. *ACS Appl Mater Interfaces.* 2018;10(44):37783–37796. doi: 10.1021/acsami.8b09757.
 47. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kaminska B, Huelsken J, Omberg L, Gevaert O, et al. Machine learning identifies Stemness features associated with oncogenic dedifferentiation. *Cell.* 2018;173(2):338–33+. doi: 10.1016/j.cell.2018.03034.
 48. Asadi-Eydivand M, Solati-Hashjin M, Fathi A, Padashi M, Abu Osman NA. Optimal design of a 3D-printed scaffold using intelligent evolutionary algorithms. *Appl Soft Comput.* 2016;39:36–47. doi: 10.1016/j.asoc.2015.11.011.
 49. Lee CS, Tyring AJ, Wu Y, Xiao S, Rokem AS, DeRuyter NP, Zhang Q, Tufail A, Wang RK, Lee AY. Generating retinal flow maps from structural optical coherence tomography with artificial intelligence. *Sci Rep.* 2019;9(1):5694. doi: 10.1038/s41598-019-42042-y.
 50. Berry C. Artificial intelligence and the dental practitioner. *BDJ In Pract.* 2019;32(4):18–19.
 51. Thomas PBM, Chan T, Nixon T, Muthusamy B, White A. Feasibility of simple machine learning approaches to support detection of non-glaucomatous visual fields in future automated glaucoma clinics. *Eye.* 2019;1476–5454, 10.1038/s41433-019-0386-2.
 52. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. *Chemmedchem.* 2007;2(6):861–873. doi: 10.1002/cmdc.200700026.
 53. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, Hickey AJ, Clark AM. Exploiting machine learning for end-to-end drug discovery and development. *Nat Mater.* 2019;18(5):435–441. doi: 10.1038/s41563-019-0338
 54. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing

- using transcriptomic data. *Mol Pharm.* 2016;13(7):2524–2530. doi: 10.1021/acs.molpharmaceut.6b00248.
55. Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, Venugopalan S, Widner K, Madams T, Cuadros J, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. *J Am Med Assoc.* 2016;316(22):2402–2410. doi: 10.1001/jama.2016.17216.
 56. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. *Nature.* 2017;542:115. doi: 10.1038/nature21056.]
 57. Janowczyk A, Madabhushi A. Deep learning for digital pathology image analysis: a comprehensive tutorial with selected use cases. *J Pathol Informatics.* 2016;7:29. doi: 10.4103/2153-3539.186902.
 58. Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, Pellikka PA, Enriquez-Sarano M, Noseworthy PA, Munger TM, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. *Nat Med.* 2019;25(1):70–74. doi: 10.1038/s41591-018-0240-2.
 59. Hannun AY, Rajpurkar P, Haghpanahi M, Tison GH, Bourn C, Turakhia MP, Ng AY. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. *Nat Med.* 2019;25(1):65–69. doi: 10.1038/s41591-018-0268-3.
 60. Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D, Basel-Salmon L, Krawitz PM, Kamphausen SB, Zenker M, et al. Identifying facial phenotypes of genetic disorders using deep learning. *Nat Med.* 2019;25(1):60–64. doi: 10.1038/s41591-018-0279-0.
 61. Bychkov D, Linder N, Turkki R, Nordling S, Kovanen PE, Verrill C, Walliander M, Lundin M, Haglund C, Lundin J. Deep learning based tissue analysis predicts outcome in colorectal cancer. *Sci Rep.* 2018;8(1):3395. doi: 10.1038/s41598-018-21758-3.
 62. Rybin VO, Xu XH, Lisanti MP, Steinberg SF. Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae - a mechanism to functionally regulate the cAMP signaling pathway. *J Biol Chem.* 2000;275(52):41447–41457. doi: 10.1074/jbc.M006951200.]
 63. Pasqualini FS, Sheehy SP, Agarwal A, Aratyn-Schaus Y, Parker KK. Structural phenotyping of stem cell-derived cardiomyocytes. *Stem Cell Rep.* 2015;4(3):340–347. doi: 10.1016/j.stemcr.2015.01.020.
 64. Chen D, Sarkar S, Candia J, Florczyk SJ, Bodhak S, Driscoll MK, Simon CG, Dunkers JP, Losert W. Machine learning based methodology to identify cell shape phenotypes associated with microenvironmental cues. *Biomaterials.* 2016;104:104–118. doi: 10.1016/j.biomaterials.2016.06.040.
 65. Sommer C, Gerlich DW. Machine learning in cell biology - teaching computers to recognize phenotypes. *J Cell Sci.* 2013;126(24):5529–5539. doi: 10.1242/jcs.123604.
 66. Schlapfer J, Wellens HJ. Computer-interpreted electrocardiograms: benefits and limitations. *J Am Coll Cardiol.* (2017) 70:1183–92. doi: 10.1016/j.jacc.2017.07.723
 67. Al'Aref SJ, Anchouche K, Singh G, Slomka PJ, Kolli KK, Kumar A, et al. Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. *Eur Heart J.* (2019) 40:1975–86. doi: 10.1093/eurheartj/ehy404

68. Hannun AY, Rajpurkar P, Haghpanahi M, Tison GH, Bourn C, Turakhia MP, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. *Nat Med.* (2019) 25:65–9. 10.1038/s41591-018-0268-3
69. Kannathal N, Acharya UR, Lim CM, Sadasivan P, Krishnan S. Classification of cardiac patient states using artificial neural networks. *Exp Clin Cardiol.* (2003) 8:206–11.
70. Zhao Q, Zhang L. ECG feature extraction and classification using wavelet transform and support vector machines. *Proceedings of the 2005 International Conference on Neural Networks and Brain.* Beijing: (2005). p. 1089–92. 10.1109/ICNNB.2005.1614807
71. Sekeli S, Sandler B, Johnston E, Pollock KG, Hill NR, Gordon J, et al. Detecting undiagnosed atrial fibrillation in UK primary care: validation of a machine learning prediction algorithm in a retrospective cohort study. *Eur J Prev Cardiol.* (2021) 28:598–605. 10.1177/2047487320942338
72. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. *Lancet.* (2019) 394:861–7. 10.1016/S0140-6736(19)31721-0
73. Lu J, Hutchens R, Hung J, Bennamoun M, McQuillan B, Briffa T, et al. Performance of multilabel machine learning models and risk stratification schemas for predicting stroke and bleeding risk in patients with non-valvular atrial fibrillation. *arXiv [Preprint].* (2022). 10.48550/arXiv.2202.01975
74. Lopez Perales CR, Van Spall HGC, Maeda S, Jimenez A, Latcu DG, Milman A, et al. Mobile health applications for the detection of atrial fibrillation: a systematic review. *Europace.* (2021) 23:11–28. 10.1093/europace/euaa139
75. Mincholé A, Rodríguez B. Artificial intelligence for the electrocardiogram. *Nat Med.* (2019) 25:22–3. 10.1038/s41591-018-0306-1
76. Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, et al. Assessment of remote heart rhythm sampling using the alivecor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. *Circulation.* (2017) 136:1784–94. 10.1161/CIRCULATIONAHA.117.030583.
77. Goldenthal IL, Sciacca RR, Riga T, Bakken S, Baumeister M, Biviano AB, et al. Recurrent atrial fibrillation/flutter detection after ablation or cardioversion using the AliveCor KardiaMobile device: iHEART results. *J Cardiovasc Electrophysiol.* (2019) 30:2220–8. 10.1111/jce.14160
78. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. *N Engl J Med.* (2019) 381:1909–17. 10.1056/NEJMoa1901183
79. Koulaouzidis G, Jadczyk T, Iakovidis DK, Koulaouzidis A, Bisnaire M, Charisopoulou D. Artificial intelligence in cardiology—a narrative review of current status. *J Clin Med.* (2022) 11:3910. 10.3390/jcm11133910
80. Benjamens S, Dhunoo P, Mesko B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. *NPJ Digit Med.* (2020) 3:118. 10.1038/s41746-020-00324-0

81. Alsharqi M, Woodward WJ, Mumith JA, Markham DC, Upton R, Leeson P. Artificial intelligence and echocardiography. *Echo Res Pract.* (2018) 5:R115–25. 10.1530/ERP-18-0056
82. Cannesson M, Tanabe M, Suffoletto MS, McNamara DM, Madan S, Lacomis JM, et al. A novel two-dimensional echocardiographic image analysis system using artificial intelligence-learned pattern recognition for rapid automated ejection fraction. *J Am Coll Cardiol.* (2007) 49:217–26. 10.1016/j.jacc.2006.08.045
83. Knackstedt C, Bekkers SC, Schummers G, Schreckenber M, Muraru D, Badano LP, et al. Fully automated versus standard tracking of left ventricular ejection fraction and longitudinal strain: the FAST-EFs multicenter study. *J Am Coll Cardiol.* (2015) 66:1456–66. 10.1016/j.jacc.2015.07.052
84. Zhang J, Gajjala S, Agrawal P, Tison GH, Hallock LA, Beussink-Nelson L, et al. Fully automated echocardiogram interpretation in clinical practice. *Circulation.* (2018) 138:1623–35. 10.1161/CIRCULATIONAHA.118.034338
85. Madani A, Arnaout R, Mofrad M, Arnaout R. Fast and accurate view classification of echocardiograms using deep learning. *NPJ Digit Med.* (2018) 1:6. 10.1038/s41746-017-0013-1
86. Sengupta PP, Huang YM, Bansal M, Ashrafi A, Fisher M, Shameer K, et al. Cognitive machine-learning algorithm for cardiac imaging: a pilot study for differentiating constrictive pericarditis from restrictive cardiomyopathy. *Circ Cardiovasc Imaging.* (2016) 9:e004330. 10.1161/CIRCIMAGING.115.004330
87. Narula S, Shameer K, Salem Omar AM, Dudley JT, Sengupta PP. Machine-learning algorithms to automate morphological and functional assessments in 2D echocardiography. *J Am Coll Cardiol.* (2016) 68:2287–95. 10.1016/j.jacc.2016.08.062
88. Moghaddasi H, Nourian S. Automatic assessment of mitral regurgitation severity based on extensive textural features on 2D echocardiography videos. *Comput Biol Med.* (2016) 73:47–55. 10.1016/j.compbiomed.2016.03.026
89. Ouyang D, He B, Ghorbani A, Yuan N, Ebinger J, Langlotz CP, et al. Video-based AI for beat-to-beat assessment of cardiac function. *Nature.* (2020) 580:252–6. 10.1038/s41586-020-2145-8
90. Krittanawong C, Virk HUI, Bangalore S, Wang Z, Johnson KW, Pinotti R, et al. Machine learning prediction in cardiovascular diseases: a meta-analysis. *Sci Rep.* (2020) 10:16057. 10.1038/s41598-020-72685-1
91. Dey D, Gaur S, Ovrehus KA, Slomka PJ, Betancur J, Goeller M, et al. Integrated prediction of lesion-specific ischaemia from quantitative coronary CT angiography using machine learning: a multicentre study. *Eur Radiol.* (2018) 28:2655–64. 10.1007/s00330-017-5223-z
92. van Rosendael AR, Maliakal G, Kolli KK, Beecy A, Al’Aref SJ, Dwivedi A, et al. Maximization of the usage of coronary CTA derived plaque information using a machine learning based algorithm to improve risk stratification; insights from the CONFIRM registry. *J Cardiovasc Comput Tomogr.* (2018) 12:204–9. 10.1016/j.jcct.2018.04.011
93. Al’Aref SJ, Maliakal G, Singh G, van Rosendael AR, Ma X, Xu Z, et al. Machine learning of clinical variables and coronary artery calcium scoring for the prediction of obstructive coronary artery disease on coronary computed tomography angiography:

- analysis from the CONFIRM registry. *Eur Heart J.* (2020) 41:359–67. 10.1093/eurheartj/ehz565
94. Han D, Kolli KK, Gransar H, Lee JH, Choi SY, Chun EJ, et al. Machine learning based risk prediction model for asymptomatic individuals who underwent coronary artery calcium score: comparison with traditional risk prediction approaches. *J Cardiovasc Comput Tomogr.* (2020) 14:168–76. 10.1016/j.jcct.2019.09.005
 95. Motwani M, Dey D, Berman DS, Germano G, Achenbach S, Al-Mallah MH, et al. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis. *Eur Heart J.* (2017) 38:500–7. 10.1093/eurheartj/ehw188
 96. Oikonomou EK, Marwan M, Desai MY, Mancio J, Alashi A, Hutt Centeno E, et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. *Lancet.* (2018) 392:929–39. 10.1016/S0140-6736(18)31114-0
 97. Arsanjani R, Xu Y, Dey D, Vahistha V, Shalev A, Nakanishi R, et al. Improved accuracy of myocardial perfusion SPECT for detection of coronary artery disease by machine learning in a large population. *J Nucl Cardiol.* (2013) 20:553–62. 10.1007/s12350-013-9706-2]
 98. Betancur J, Commandeur F, Motlagh M, Sharir T, Einstein AJ, Bokhari S, et al. Deep learning for prediction of obstructive disease from fast myocardial perfusion SPECT: a Multicenter study. *JACC Cardiovasc Imaging.* (2018) 11:1654–63. 10.1016/j.jimg.2018.01.020
 99. Hu L-H, Betancur J, Sharir T, Einstein AJ, Bokhari S, Fish MB, et al. Machine learning predicts per-vessel early coronary revascularization after fast myocardial perfusion SPECT: results from multicentre REFINE SPECT registry. *Eur Heart J Cardiovasc Imaging.* (2020) 21:549–59. 10.1093/ehjci/jez177
 100. Bustin A, Fuin N, Botnar RM, Prieto C. From compressed-sensing to artificial intelligence-based cardiac MRI reconstruction. *Front Cardiovasc Med.* (2020) 7:17. 10.3389/fcvm.2020.00017
 101. Seetharam K, Brito D, Farjo PD, Sengupta PP. The role of artificial intelligence in cardiovascular imaging: state of the art review. *FroCardiovasc Med.* (2020) 7:618849. 10.3389/fcvm.2020.6188
 102. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells. *Mol Ther.* 2015;23(9):1475–1485. doi: 10.1038/mt.2015.100.
 103. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. *Nat Biotechnol.* 2014;32(4):347. doi: 10.1038/nbt.2842.
 104. Mosqueira Diogo, Mannhardt Ingra, Bhagwan Jamie R, Lis-Slimak Katarzyna, Katili Puspita, Scott Elizabeth, Hassan Mustafa, Prondzynski Maksymilian, Harmer Stephen C, Tinker Andrew, Smith James G W, Carrier Lucie, Williams Philip M, Gaffney Daniel, Eschenhagen Thomas, Hansen Arne, Denning Chris. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. *European Heart Journal.* 2018;39(43):3879–3892. doi: 10.1093/eurheartj/ehy249.

105. Jehuda RB, Eisen B, Shemer Y, Mekies LN, Szantai A, Reiter I, Cui H, Guan K, Haron-Khun S, Freimark D. CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities. *Heart Rhythm*. 2018;15(2):267–276. doi: 10.1016/j.hrthm.2017.09.024.
106. Cong L., Ran F. A., Cox D., Lin S., Barretto R., Habib N., Hsu P. D., Wu X., Jiang W., Marraffini L. A., Zhang F. Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science*. 2013;339(6121):819–823. doi: 10.1126/science.1231143

ORIGINALITY REPORT

13%

SIMILARITY INDEX

PRIMARY SOURCES

1	jbioleng.biomedcentral.com Internet	256 words — 3%
2	www.ncbi.nlm.nih.gov Internet	183 words — 2%
3	www.mdpi.com Internet	140 words — 2%
4	vshows.com Internet	44 words — 1%
5	interventions.onlinejacc.org Internet	38 words — < 1%
6	www.aedbrands.com Internet	37 words — < 1%
7	www.tandfonline.com Internet	37 words — < 1%
8	Joshua T. Maxwell, Chunhui Xu. "Stem-Cell-Derived Cardiomyocytes Grow Up: Start Young and Train Harder", Cell Stem Cell, 2018 Crossref	30 words — < 1%
9	royalsocietypublishing.org	

34	research-management.mq.edu.au Internet	8 words — < 1%
35	worldwidescience.org Internet	8 words — < 1%
36	"Cardiac Repolarization", Springer Science and Business Media LLC, 2020 Crossref	7 words — < 1%
37	Xiaoyin Li, Xiao Liu, Xiaoyan Deng, Yubo Fan. "Interplay between Artificial Intelligence and Biomechanics Modeling in the Cardiovascular Disease Prediction", Biomedicines, 2022 Crossref	7 words — < 1%
38	Addison Gearhart, Sharib Gaffar, Anthony C. Chang. "A primer on artificial intelligence for the paediatric cardiologist", Cardiology in the Young, 2020 Crossref	6 words — < 1%

EXCLUDE QUOTES ON
EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES OFF
EXCLUDE MATCHES OFF